NC
OCUL icon

nVerses Capital’s Ocular Therapeutix OCUL Stock Holding History

nVerses Capital’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$256K Buy
+26,117
New +$237K 0.39% 96

Other funds holding OCUL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

nVerses Capital's OCUL Position: Q2 2026 in Review

nVerses Capital opened a new position in Ocular Therapeutix (OCUL) in Q2 2026: 26,117 shares worth $256K. The stake represents 0.39% of the portfolio and ranks #96 among its holdings.

172 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • nVerses Capital held 26,117 shares of Ocular Therapeutix worth $256K as of Q2 2026.
  • Ocular Therapeutix was a new nVerses Capital position in Q2 2026.
  • Ocular Therapeutix made up 0.39% of nVerses Capital's portfolio in Q2 2026, its #96 holding.
  • 172 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.